KALA_OUT_1 [2025-04-29 08:41:08 -0400] 5158 Bytes | 1428 tokens | Cum: 1428 tkns (17.85% of 8k)
==========================================================================

Good morrow, traveler. 'Tis 8:41 AM on Tue Apr 29, 2025, and lo, KALA BIO (KALA) hath gained ground from $3.18 unto $3.49. Shall we seize upon this chance, or tarry and watch?

--- COMPANY PROFILE ---
Company: KALA BIO (KALA)
IPO: 2017-07-20 (7 Years Ago)
Market Cap: $21,228,389
Shares Outstanding: 6,450,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Here’s a list of headlines for KALA BIO:

Mar-31-25 08:00AM - KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Feb-26-25 08:00AM - KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
Feb-12-25 08:00AM - KALA BIO Announces Chief Executive Officer Transition
Dec-30-24 08:00AM - KALA BIO Announces $10,750,000 Private Placement
Nov-27-24 08:00AM - KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
Nov-12-24 08:00AM - KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Aug-08-24 08:00AM - KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Aug-06-24 01:53PM - KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024
Aug-06-24 01:53PM 08:00AM - KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jun-27-24 08:00AM - KALA BIO Announces $12,500,000 Private Placement
May-29-24 08:00AM - KALA BIO to Present at Jefferies Global Healthcare Conference
May-21-24 01:13PM - Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)
May-21-24 01:13PM 11:17AM - Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
May-14-24 10:54PM - KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024
May-14-24 10:54PM 04:05PM - KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr-02-24 07:53AM - KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
Mar-29-24 08:00AM - KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Feb-26-24 08:00AM - KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
Feb-06-24 08:00AM - KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan-19-24 04:01PM - KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov-13-23 08:00AM - KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sep-20-23 04:01PM - KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-12T13:00:00Z - KALA BIO Announces Chief Executive Officer Transition
B2 - 2024-11-27T13:00:00Z - KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
B3 - 2024-05-29T12:00:00Z - KALA BIO to Present at Jefferies Global Healthcare Conference
B4 - 2024-04-04T13:55:06Z - Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
B5 - 2024-03-29T12:00:00Z - KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
B6 - 2024-02-26T13:00:00Z - KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for KALA BIO (KALA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

KALA_OUT_3 [2025-04-29 08:41:09 -0400] 818 Bytes | 220 tokens | Cum: 1650 tkns (20.62% of 8k)
==========================================================================

Showing B4 (chunk 1 of 1): B4:
**Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2250503/does-kala-bio-kala-have-the-potential-to-rally-15283-as-wall-street-analysts-expectThe mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_5 [2025-04-29 08:41:10 -0400] 873 Bytes | 266 tokens | Cum: 1918 tkns (23.97% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T05:00:00Z - ...
A2 - 2025-04-22T17:05:43Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Akso Health (NASDAQ:AHG), Adagio Medica...
A3 - 2025-04-11T17:40:07Z - KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com...
A4 - 2025-04-11T17:40:06Z - KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com...
A5 - 2025-04-11T17:39:23Z - KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KALA_OUT_7 [2025-04-29 08:41:10 -0400] 888 Bytes | 249 tokens | Cum: 2169 tkns (27.11% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
****Date: 2025-04-23Source: {'uri': 'finviz.com', 'dataType': 'news', 'title': 'finviz.com'}URL: https://finviz.com/quote.ashx?t=KALA&ty=c&p=d&b=1Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc. Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_9 [2025-04-29 08:41:11 -0400] 1094 Bytes | 276 tokens | Cum: 2447 tkns (30.59% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes thereto appearing at...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2024 and provided a general business and corporate update. The full text of the press release is furnished as ...

S4 - 2024-12-30 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Securities Purchase Agrmt

On December 29, 2024, KALA BIO, Inc. (the Company) entered into a Securities Purchase Agrmt (the Securities Purchase Agrmt) with certain institutional investors named therein (the Pur...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KALA_OUT_11 [2025-04-29 08:41:11 -0400] 1181 Bytes | 244 tokens | Cum: 2693 tkns (33.66% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes thereto appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See Special Note Regarding Forward-Looking Statements and Industry Data. Because of many factors, including those factors set forth in the Risk Factors section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_13 [2025-04-29 08:41:12 -0400] 1181 Bytes | 278 tokens | Cum: 2973 tkns (37.16% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye. Our product candidate, KPI-012, which we acquired from Combangio, Inc., or Combangio, on November 15, 2021, is a mesenchymal stem cell secretome, or MSC-S, and is currently in clinical development for the treatment of persistent corneal epithelial defects, or PCED, a rare disease of impaired corneal healing. Based on the positive results of a Phase 1b clinical safety and efficacy trial of KPI-012 in patients with PCED, along with favorable preclinical safety and efficacy results, we submitted an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_15 [2025-04-29 08:41:13 -0400] 1181 Bytes | 299 tokens | Cum: 3274 tkns (40.92% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): , which was accepted in December 2022. In February 2023, we dosed our first patient in our CHASE ( C orneal H ealing A fter SE cretome therapy) Phase 2b clinical trial of KPI-012 for PCED in the United States, or the CHASE trial.

The CHASE trial is comprised of two patient cohorts. On March 27, 2023, we announced positive safety data from the first cohort of the CHASE trial, which is an open-label study to evaluate the safety of the high dose of KPI-012 ophthalmic solution (3 U/mL) dosed topically four times per day, or QID, in two patients. Both patients in the first cohort successfully completed eight weeks of dosing with no safety issues observed. We have initiated the second and final patient cohort of the CHASE trial in the United States, which is a multicenter, randomized, double-masked, vehicle-controlled, parallel-group trial to evaluate the safety and efficacy of two doses of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_17 [2025-04-29 08:41:14 -0400] 1181 Bytes | 271 tokens | Cum: 3547 tkns (44.34% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): KPI-012 ophthalmic solution (3 U/mL and 1 U/mL) versus vehicle dosed topically QID for 56 days in approximately 90 adult patients. To date, we have opened 45 trial sites for the CHASE trial in the United States. We have also initiated several clinical trial sites in Argentina for the CHASE trial and we are in the process of initiating additional clinical trial sites in Latin America.

The primary endpoint of the CHASE trial is the complete healing of the PCED as measured by corneal fluorescein staining. To date, we have randomized 87 patients. Upon review of the only masked screening and baseline data, we have decided to extend enrollment to account for 13 patients who were enrolled and treated based on the investigators determination of the presence of a PCED which was subsequently not verified by the central reading center. We are targeting reporting topline safety and efficacy data fr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_19 [2025-04-29 08:41:18 -0400] 1181 Bytes | 276 tokens | Cum: 3825 tkns (47.81% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): om the CHASE trial in the third quarter of 2025. If the results are positive, and subject to discussion with regulatory authorities, we believe this trial could serve as the first of two pivotal trials required to support the submission of a Biologics License Application, or BLA, for KPI-012 to the FDA.

KPI-012 has received Orphan Drug and Fast Track designations from the FDA for the treatment of PCED.

We believe the multifactorial mechanism of action of KPI-012 also makes our MSC-S a platform technology. We are evaluating the potential development of KPI-012 for additional rare front-of-the-eye diseases, such as for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision. In addition, we have initiated preclinical studies under our KPI-014 program to evaluate the utility of our MSC-S platform for inherited retinal degenerative diseases, such

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_21 [2025-04-29 08:41:19 -0400] 790 Bytes | 210 tokens | Cum: 4037 tkns (50.46% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): as Retinitis Pigmentosa and Stargardt Disease. We expect to commercialize in the United States any of our product candidates that receive marketing approval.

We previously developed and commercialized two marketed products, EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the

treatment of po...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

KALA_OUT_23 [2025-04-29 08:41:24 -0400] 6006 Bytes | 1611 tokens | Cum: 5650 tkns (70.62% of 8k)
==========================================================================

This is our set of metrics for KALA BIO.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 57,187 | Perf Month: -43.51% | Option/Short: No / Yes | Sales Y/Y TTM: -100.00% |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 55.93K | Perf Quarter: -57.32% | Short Float: 5.32% | ROE: -388.29% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 1.00 | Index: - | Short Ratio: 5.06 | ROI: -113.71% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 36.93 | Market Cap: 23.04M | Short Interest: 0.28M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.44 | Shs Outstand: 6.09M | Beta: -1.88 | EPS Surprise: 23.68% |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: -6.45% | Shs Float: 5.31M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: -36.95% | Inst Own: 44.34% | Sales past 5Y: -16.79% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -44.36% | Insider Own: 17.76% | Employees: 38 | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 8.51% | Insider Trans: 35.24% | Debt/Eq: 2.62 | |
+--------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by KALA BIO officers or majority shareholders (if available).

Inside Trans: KALA BIO, Inc. (KALA) by Bazemore Todd (SEE REMARKS) on 2025-03-07
- Stock Option (right to buy): 45200 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -38963000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.57
Average Volume: 50407.55
30-Day High: 5.73
30-Day Low: 2.945

[Detailed Financials: Q3 2024]
- Total Assets: $54,079,000.00
- Total Liabilities: $47,220,000.00
- Total Equity: $6,859,000.00
- Current Assets: $51,279,000.00
- Current Liabilities: $23,867,000.00

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: $-8,950,000.00
- Gross Profit: N/A
- Operating Income: $-9,988,000.00
- Earnings Per Share (EPS): -1.93

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-4,995,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $61,606,000.00
- Total Liabilities: $47,889,000.00
- Total Equity: $13,717,000.00
- Current Assets: $58,853,000.00
- Current Liabilities: $19,190,000.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-9,579,000.00
- Gross Profit: N/A
- Operating Income: $-9,605,000.00
- Earnings Per Share (EPS): -3.16

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,719,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of KALA BIO (KALA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about KALA BIO.

2) MARKET_SCORE[]
This conversation was initiated because KALA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for KALA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, KALA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect KALA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of KALA BIO.

11) ETHICAL_RATING[]
Rate KALA BIO’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of KALA BIO.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

KALA_IN_25 [2025-04-29 08:41:25 -0400] 126 Bytes | 29 tokens | Cum: 5874 tkns (73.42% of 8k)
==========================================================================

====================================
[2025-04-29 08:41:25] # Analysis Completed
Elapsed Time: 18.66 seconds